









市場行情
/
股票
/
nasdaq-alks
/

Alkermes Plc

ALKS

28.395USD

-0.125-0.44%

交易中（美東）報價延遲15分鐘

4.69B總市值

13.76本益比TTM



Alkermes Plc

28.395

-0.125-0.44%

概覽公司財務分析

概覽

公司

財務

分析

關於 Alkermes Plc 公司

Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Alkermes Plc簡介



公司代碼ALKS

公司名稱Alkermes Plc

上市日期Jul 16, 1991

CEOPops (Richard F)

員工數量1800

證券類型Ordinary Share

年結日Jul 16

公司地址Connaught House

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Ireland

郵編D04 C5Y6

電話35317728000

網址https://www.alkermes.com/

公司代碼ALKS

上市日期Jul 16, 1991

CEOPops (Richard F)

Alkermes Plc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

65.74K

-5.74%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

Dr. Cato T. Laurencin, M.D., Ph.D.

Independent Director

29.10K

+26.46%

Dr. Christopher I. Wright, M.D., Ph.D.

Independent Director

23.01K

+12.23%

Ms. Nancy S. Lurker

Independent Director

10.71K

+131.91%

Dr. Nancy L. Snyderman, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Richard F. Pops

Chairman of the Board, Chief Executive Officer

1.29M

Mr. David Joseph Gaffin

Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary

205.37K

+0.55%

Mr. Shane M. Cooke

Independent Director

103.74K

+3.84%

Dr. Craig C. Hopkinson, M.D.

Executive Vice President, Research and Development and Chief Medical Officer

65.74K

-5.74%

Mr. Brian P. Mckeon

Independent Director

43.87K

+16.12%

Mr. Frank Anders (Andy) Wilson, CPA

Lead Independent Director

31.08K

+24.36%

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

其他

21.09M

5.40%

由於公司未披露，未能獲取相關數據

業務

地區

業務USD

名稱

營收

佔比

VIVITROL

121.66M

31.14%

ARISTADA

101.30M

25.93%

LYBALVI

84.28M

21.57%

Royalty Revenue - VUMERITY

32.02M

8.20%

Royalty-INVEGA SUSTENNA/XEPLION & INVEGA TRINZA/TREVICTA

30.32M

7.76%

其他

21.09M

5.40%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

14.33%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

6.09%

State Street Investment Management (US)

5.17%

Baker Bros. Advisors LP

4.90%

其他

58.54%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

14.33%

The Vanguard Group, Inc.

10.98%

T. Rowe Price Associates, Inc.

6.09%

State Street Investment Management (US)

5.17%

Baker Bros. Advisors LP

4.90%

其他

58.54%

股東類型

持股股東

佔比

Investment Advisor

54.03%

Investment Advisor/Hedge Fund

28.01%

Hedge Fund

17.63%

Pension Fund

2.30%

Research Firm

2.18%

Individual Investor

1.48%

Sovereign Wealth Fund

1.18%

Bank and Trust

0.44%

Private Equity

0.42%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

744

175.23M

117.54%

-23.12K

2025Q3

767

175.30M

122.16%

+2.11M

2025Q2

769

173.38M

125.62%

-4.15M

2025Q1

759

177.46M

124.05%

-27.05M

2024Q4

734

172.08M

130.58%

-12.03M

2024Q3

705

184.36M

134.23%

-884.11K

2024Q2

687

185.17M

126.42%

+3.87M

2024Q1

659

181.61M

124.10%

-28.36M

2023Q4

633

182.01M

111.83%

+12.84M

2023Q3

601

169.31M

104.05%

+9.33M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

23.73M

14.37%

-251.67K

-1.05%

Jun 30, 2025

The Vanguard Group, Inc.

18.45M

11.18%

+290.40K

+1.60%

Jun 30, 2025

T. Rowe Price Associates, Inc.

9.86M

5.97%

-1.76M

-15.13%

Jun 30, 2025

State Street Investment Management (US)

8.21M

4.97%

+185.59K

+2.31%

Jun 30, 2025

Baker Bros. Advisors LP

6.41M

3.88%

+1.93M

+42.99%

Jun 30, 2025

Renaissance Technologies LLC

5.81M

3.52%

+71.33K

+1.24%

Jun 30, 2025

American Century Investment Management, Inc.

3.66M

2.22%

+191.55K

+5.53%

Jun 30, 2025

Geode Capital Management, L.L.C.

4.02M

2.44%

+83.86K

+2.13%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.10M

1.88%

+105.63K

+3.53%

Jun 30, 2025

JP Morgan Asset Management

3.95M

2.39%

-179.85K

-4.36%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AdvisorShares Psychedelics ETF

7.31%

iShares Neuroscience and Healthcare ETF

3.82%

First Trust NYSE Arca Biotechnology Index Fund

3.3%

Invesco S&P SmallCap Health Care ETF

3.1%

ALPS Medical Breakthroughs ETF

2.07%

Knowledge Leaders Developed World ETF

1.69%

Langar Global HealthTech ETF

1.44%

State Street SPDR S&P Biotech ETF

1.35%

Abacus FCF International Leaders ETF

1.34%

Invesco S&P SmallCap Quality ETF

1.32%

AdvisorShares Psychedelics ETF

佔比7.31%

iShares Neuroscience and Healthcare ETF

佔比3.82%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.3%

Invesco S&P SmallCap Health Care ETF

佔比3.1%

ALPS Medical Breakthroughs ETF

佔比2.07%

Knowledge Leaders Developed World ETF

佔比1.69%

Langar Global HealthTech ETF

佔比1.44%

State Street SPDR S&P Biotech ETF

佔比1.35%

Abacus FCF International Leaders ETF

佔比1.34%

Invesco S&P SmallCap Quality ETF

佔比1.32%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Alkermes Plc的前五大股東是誰？



Alkermes Plc的前五大股東如下：
BlackRock Institutional Trust Company, N.A.
持有股份：23.73M
佔總股份比例：14.37%。
The Vanguard Group, Inc.
持有股份：18.45M
佔總股份比例：11.18%。
T. Rowe Price Associates, Inc.
持有股份：9.86M
佔總股份比例：5.97%。
State Street Investment Management (US)
持有股份：8.21M
佔總股份比例：4.97%。
Baker Bros. Advisors LP
持有股份：6.41M
佔總股份比例：3.88%。